Expression of DNA Topoisomerase II and P-Glycoprotein in Breast Cancer / 대한암학회지
Journal of the Korean Cancer Association
;
: 242-249, 1997.
Article
in Korean
| WPRIM
| ID: wpr-123099
ABSTRACT
PURPOSE:
To determine whether the expression of DNA topoisomerase II and P-glycoprotein are of prognostic value. MATERIALS ANDMETHODS:
We evaluated the expression of DNA topoisomerase II and P-glycoprotein immunohistochemically in a retrospective study of samples from 44 patients with breast cancer. Thirty two among 44 patients (72.7%) received chemotherapeutic treatments (CMF or FAC protocol) and/or tamoxifen postoperatively.RESULTS:
P-glycoprotein was detected in the 27 samples of 44 patients (61.3%). The expression of P-glycoprotein was increased in the patients older than 50 years, with distant metastases, and with death on follow-up. DNA topoisomerase II was detected in the 34 samples of 44 patients (77.2%). The expression of topoisomerase II was increased in the patients younger than 50 years, with recurrent tumor, with distant metastases, and with death on follow-up. The expression of P-glycoprotein and topoisomerase II was not correlated with other clinico-pathological factors including the size of primary tumor, involvement of lymph node, histologic grade, and clinical stage. The correlation between expression of P-glycoprotein and topoisomerase II was not significant.CONCLUSION:
The immunohistochemical evaluation of P-glycoprotein and topoisomerase II before treatment in breast cancer has little clinical prognostic value.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Tamoxifen
/
Breast
/
Breast Neoplasms
/
DNA
/
Immunohistochemistry
/
Retrospective Studies
/
Follow-Up Studies
/
DNA Topoisomerases, Type II
/
DNA Topoisomerases, Type I
/
ATP Binding Cassette Transporter, Subfamily B, Member 1
Type of study:
Practice guideline
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
Korean
Journal:
Journal of the Korean Cancer Association
Year:
1997
Type:
Article
Similar
MEDLINE
...
LILACS
LIS